The fast pace of innovation in IT offers compelling investment opportunities
Truffle Capital is a pioneer investor in the exciting field of Energy
Biotechnology has radically transformed medicine over the past 25 years
Neovacs, a spin-off from Pierre & Marie Curie University in Paris, is a biotechnology company focused on an active immunotherapy technology platform, with applications in autoimmune diseases and other chronic conditions. It was founded by Professor Daniel Zagury, MD, PhD, one of the world’s leading immunologists.
The Company’s lead program, an immunotherapy targeting certain inflammatory diseases, is currently in a Phase 1/2 study in subjects with Crohn’s Disease and a Phase 2 study in rheumatoid arthritis patients who have failed at least one prior TNFa inhibitor.
Truffle Capital owns 40% of Neovacs and is Neovacs’ first shareholder. Neovacs was listed on Alternext of NYSE-Euronext in April 2010, thus raising 10m€. This was the first successful IPO in the French biotech sector since 2008.
Truffle Capital board members: Dr. Philippe Pouletty, Jean-Jacques Bertrand
L’intervention de Guy-Charles Fanneau de la Horie, Directeur Général de Neovacs, lors de la 2e édition du Truffle Exchange organisé le 20 mars 2012.
Interview de Guy-Charles Fanneau de la Horie, Directeur Général de Neovacs, lors de la deuxième édition de Truffle Exchange, quand la bourse rencontre l’innovation, le 20 mars 2012